Effects of once-weekly semaglutide vs canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 trial

被引：0
|
作者：
McCrimmon, R. J. [1 ]
Catarig, A. [2 ]
Frias, J. P. [3 ]
Lausvig, N. L. [2 ]
le Roux, C. W. [4 ]
Thielke, D. [2 ]
Lingvay, I. [5 ]
机构：
[1] Univ Dundee, Dundee, Scotland
[2] Novo Nordisk AS, Soborg, Denmark
[3] Natl Res Inst, Los Angeles, CA USA
[4] Univ Coll Dublin, Dublin, Ireland
[5] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
来源：
DIABETOLOGIA | 2019年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
54
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [1] Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
    McCrimmon, Rory J.
    Catarig, Andrei-Mircea
    Frias, Juan P.
    Lausvig, Nanna L.
    le Roux, Carel W.
    Thielke, Desiree
    Lingvay, Ildiko
    DIABETOLOGIA, 2020, 63 (03) : 473 - 485
  • [2] Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial
    Rory J. McCrimmon
    Andrei-Mircea Catarig
    Juan P. Frias
    Nanna L. Lausvig
    Carel W. le Roux
    Desirée Thielke
    Ildiko Lingvay
    Diabetologia, 2020, 63 : 473 - 485
  • [3] Once-weekly semaglutide vs canagliflozin in type 2 diabetes: results of the SUSTAIN 8 trial
    Lingvay, I.
    Catarig, A.
    Frias, J. P.
    Kumar, H.
    Lausvig, N. L.
    le Roux, C. W.
    Thielke, D.
    Viljoen, A.
    McCrimmon, R. J.
    DIABETOLOGIA, 2019, 62 : S27 - S28
  • [4] Efficacy and safety of once-weekly semaglutide monotherapy vs placebo in subjects with Type 2 diabetes (SUSTAIN 1)
    Sorli, C.
    Harashima, S-I
    Tsoukas, G.
    Unger, J.
    Karsbol, J. D.
    Bain, S.
    DIABETIC MEDICINE, 2017, 34 : 145 - 145
  • [5] Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial
    Frias, Juan P.
    Auerbach, Pernille
    Bajaj, Harpreet S.
    Fukushima, Yasushi
    Lingvay, Ildiko
    Macura, Stanislava
    Sondergaard, Anette L.
    Tankova, Tsvetalina
    Tentolouris, Nikolaos
    Buse, John B.
    DIABETES, 2021, 70
  • [6] Efficacy and Safety of Once-Weekly Semaglutide vs. Exenatide ER in Subjects with Type 2 Diabetes (SUSTAIN 3)
    Ahmann, Andrew J.
    Capehorn, Matthew
    Charpentier, Guillaume
    Dotta, Francesco
    Henkel, Elena
    Lingvay, Ildiko
    Holst, Anders Gaarsdal
    Chang, Denise
    Aroda, Vanita R.
    DIABETES, 2016, 65 : A49 - A49
  • [7] Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
    Ildiko Lingvay
    Malik Benamar
    Liming Chen
    Ariel Fu
    Esteban Jódar
    Tomoyuki Nishida
    Jean-Pierre Riveline
    Daisuke Yabe
    Thomas Zueger
    Rosângela Réa
    Diabetologia, 2025, 68 (4) : 739 - 751
  • [8] Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials
    Jendle, Johan
    Birkenfeld, Andreas L.
    Polonsky, William H.
    Silver, Robert
    Uusinarkaus, Kari
    Hansen, Thomas
    Hakan-Bloch, Jonas
    Tadayon, Sayeh
    Davies, Melanie J.
    DIABETES OBESITY & METABOLISM, 2019, 21 (10): : 2315 - 2326
  • [9] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Pierre Johansen
    Jonas Håkan-Bloch
    Aiden R. Liu
    Peter G. Bech
    Sofie Persson
    Lawrence A. Leiter
    PharmacoEconomics - Open, 2019, 3 : 537 - 550
  • [10] Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
    Johansen, Pierre
    Hakan-Bloch, Jonas
    Liu, Aiden R.
    Bech, Peter G.
    Persson, Sofie
    Leiter, Lawrence A.
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 537 - 550
12345